Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Feb;10(4):1314-1326.
doi: 10.1002/cam4.3730. Epub 2021 Jan 25.

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Juan-Manuel Sancho  1 , Rubén Fernández-Alvarez  2 , Francisco Gual-Capllonch  3 , Esther González-García  2 , Carlos Grande  4 , Norma Gutiérrez  5 , María-Jesús Peñarrubia  6 , Ana Batlle-López  7 , Eva González-Barca  8 , José-María Guinea  9 , Eva Gimeno  10 , Francisco-Javier Peñalver  11 , Miguel Fuertes  12 , Mariana Bastos  13 , José-Ángel Hernández-Rivas  14 , José-María Moraleda  15 , Olga García  1 , Marc Sorigué  1 , Alejandro Martin  5
Affiliations
Clinical Trial

R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

Juan-Manuel Sancho et al. Cancer Med. 2021 Feb.

Abstract

The use of non-pegylated liposomal doxorubicin (Myocet® ) in diffuse large B-cell lymphoma (DLBCL) has been investigated in retrospective and single-arm prospective studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R-CHOP or investigational R-COMP (with Myocet® instead of conventional doxorubicin). The primary end point was to evaluate the differences in subclinical cardiotoxicity, defined as decrease in LVEF to <55% at the end of treatment. Secondary objectives were efficacy, safety, and variations of troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and LVEF along follow-up. Ninety patients were included, 45 in each group. No differences were observed in the percentage of patients with LVEF <55% at end of treatment (11% in R-CHOP arm vs. 7% in R-COMP arm, p = 0.697) or at 4 months (10% vs. 6%, respectively, p = 0.667) and 12 months (8% vs. 7%, respectively, p = 1). However, a higher percentage of R-CHOP compared with R-COMP patients showed increased troponin levels in cycle 6 (100% vs. 63%, p = 0.001) and at 1 month after treatment (88% vs. 56%, respectively, p = 0.015). Cardiovascular adverse events were seen in five R-CHOP patients (nine episodes, four grade ≥3) and in four R-COMP patients (five episodes, all grade 1-2). No significant differences in efficacy were observed. In conclusion, R-COMP is a feasible immunochemotherapy schedule for DLBCL patients ≥60 years, with similar efficacy to R-CHOP. However, the use of non-pegylated doxorubicin instead of conventional doxorubicin was not associated with less early cardiotoxicity, although some reduced cardiac safety signals were observed. Trial registration: ClinicalTrials.gov Identifier: NCT02012088.

Keywords: N-terminal pro-B-type natriuretic peptide; cardiotoxicity; diffuse large B-cell lymphoma; liposomal doxorubicin; troponin.

PubMed Disclaimer

Conflict of interest statement

JMS has received honoraria from Roche, Gilead, Janssen, Celgene, Servier, Novartis, Mundipharma, Sanofi, Kern‐Pharma, and Takeda, and was a Member of the Board of Directors or advisory committees for Roche, Janssen, Gilead, Celgene, Novartis, Bristol Myers, and Celltrion. NG has received honoraria from Roche and Janssen. EG has participated in advisory committees for Abbvie, Janssen, and Gilead. JAHR received honoraria and research funding from Roche, Janssen, Celgene, and Gilead. JMGDC received honoraria from Novartis and Alexion y Pfizer.

Figures

FIGURE 1
FIGURE 1
Flowchart of patients
FIGURE 2
FIGURE 2
Event‐free survival (EFS), progression‐free survival (PFS), and overall survival (OS) probabilities for the overall series
FIGURE 3
FIGURE 3
Event‐free survival (EFS), progression‐free survival (PFS), and overall survival (OS) probabilities by treatment group (RCHOP and R‐COMP groups represented in the continuous and dashed lines, respectively)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. González‐Barca E, Coronado M, Martín A, et al; Spanish Lymphoma Group (GELTAMO) . Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow‐up of diffuse large B‐cell lymphoma. Oncotarget. 2018;9:32383‐32399. - PMC - PubMed
    1. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome‐encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444‐1454. - PubMed
    1. Nousianen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86:1697‐1700. - PMC - PubMed
    1. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non‐Hodgkin's lymphoma. Ann Oncol. 2003;14:277‐281. - PubMed
    1. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high‐dose chemotherapy. Circulation. 2004;109:2749‐2754. - PubMed

Publication types

MeSH terms

Associated data